Thermofisher
News

Sun Pharma announces FDA tentative approval for generic Cymbalta

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

News

Regulatory Strategy for Early-Stage Biotech and Medtech Companies

Early-stage companies tend to focus on the science and...
BioPharma

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...
Business & Industry

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...
- Advertisement -

Sun Pharmaceutical Industries Ltd. announced US FDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector
Subscribe for Free

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Previous article
Lilly and Acrux Receive FDA Approval for Axiron Topical Solution CIII
Next article
Vertex Completes New Drug Application for Telaprevir for Hepatitis C

Related stories

News

Regulatory Strategy for Early-Stage Biotech and Medtech Companies

Early-stage companies tend to focus on the science and...
BioPharma

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...
Business & Industry

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...
Business & Industry

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
Equipment Retrofit Planning Improving Pharmaceutical Production Continuity

Equipment Retrofit Planning Improving Pharmaceutical Production Continuity

biotech regulatory strategy

Regulatory Strategy for Early-Stage Biotech and Medtech Companies